Galderma announced that Tri-Luma (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) cream is available again for short-term treatment (up to 8 weeks) of moderate to severe melasma of the face, in the presence of measures for sun avoidance, including the use of sunscreens.